A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.
Carducci, Michael A. MD 1,*; Saad, Fred MD 2; Abrahamsson, Per-Anders MD 3; Dearnaley, David P. MD 4; Schulman, Claude C. MD 5; North, Scott A. MD 6; Sleep, Darryl J. MD 7; Isaacson, Jeffrey D. PhD 7; Nelson, Joel B. MD 8; for the Atrasentan Phase III Study Group Institutions. 8
110(9):1959-1966, November 1, 2007.
(Format: HTML, PDF)